generated from CDCgov/template
-
Notifications
You must be signed in to change notification settings - Fork 9
Commit
This commit does not belong to any branch on this repository, and may belong to a fork outside of the repository.
Added two new CA sample ORU files with their final HL7
- Loading branch information
1 parent
b1d678b
commit 026e2a7
Showing
4 changed files
with
261 additions
and
0 deletions.
There are no files selected for viewing
130 changes: 130 additions & 0 deletions
130
examples/CA/014_CA_ORU_R01_CDPH_produced_from_UCSD_order_189394505_0_initial_message.hl7
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
| Original file line number | Diff line number | Diff line change |
|---|---|---|
| @@ -0,0 +1,130 @@ | ||
| MSH|^~\&|SISGDSP|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^^L,M,N|20240722021721||ORU^R01^ORU_R01|243747680|T|2.5.1 | ||
| PID|1||80008667^^^&NPI^MR||ADT^BOY A ARTICHOKE^^^^^B||202305250959|M||2076-8^Native Hawaiian or Other Pacific Islander||||||||||||2186-5^Not Hispanic or Latino||Y|1 | ||
| NK1|1|ADT^ARTICHOKE|MTH^Mother | ||
| ORC|RE|7271235330^FormNumber||189394505^HospOrdNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^NPI|||||||||^^^^^^^^^R797| N 054TS ARALC, TS102 E^^SAN DIEGO^CA^99999-9999 | ||
| OBR|1|7271235330^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202407171229|||||||||^HUBBARD^EUSTRATIA||||||20240722021721|||F | ||
| OBR|2|7271235330^FormNumber||57128-1^Newborn Screening Report summary panel|||202407171229|||||||||^HUBBARD^EUSTRATIA||||||20240722021721|||F | ||
| OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20240722021721 | ||
| OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20240722021721 | ||
| OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20240722021721 | ||
| OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA12566-8^SCID^LN|||N|||F|||20240722021721 | ||
| OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20240722021721 | ||
| OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\EG 4389EVA EESEN, TS054 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL W 057DR HCLE, TS016 E, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Duplicate\.br\\.br\Follow-up:\.br\\.br\Acyl Carnitine Panel: Reference Ranges for acylcarnitines are based on specimens collected on newborns who are less than 10 days old. \.br\\.br\SCID: A liquid blood specimen for CBC differential and flow cytometry at Quest Diagnostics is required to rule out or confirm SCID or a related immune disorder. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at at . \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, Pompe Disease Tier-1, MPS I Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\\.br\|||N|||F|||20240722021721 | ||
| OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20240722021721 | ||
| OBR|3|7271235330^FormNumber||57717-1^Newborn screen card data panel|||202407171229|||||||||^HUBBARD^EUSTRATIA||||||20240722021721|||F | ||
| OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20240722021721 | ||
| OBX|2|NM|8339-4^Birthweight^LN|1|3175|grams||N|||F|||20240722021721 | ||
| OBX|3|TM|57715-5^Time of birth^LN|1|0959|||N|||F|||20240722021721 | ||
| OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20240722021721 | ||
| OBX|5|NM|73806-2^Newborn age in hours^LN|1|419|day(s)||N|||F|||20240722021721 | ||
| OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20240722021721 | ||
| OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20240722021721 | ||
| OBX|8|TX|^^^99717-5^Accession Number^L|1|200-85-428/21-2024-21|||N|||F|||20240722021721 | ||
| OBX|9|TX|62324-9^Post-discharge provider name^LN|1|GENEEN GIN|||N|||F|||20240722021721 | ||
| OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|N 054TS ARALC, TS102 E SAN DIEGO CA 99999-9999 USA|||N|||F|||20240722021721 | ||
| OBR|4|7271235330^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202407171229|||||||||^HUBBARD^EUSTRATIA||||||20240722021721|||F | ||
| OBR|5|7271235330^FormNumber||53261-4^Amino acid newborn screen panel|||202407171229|||||||||^HUBBARD^EUSTRATIA||||||20240722021721|||F | ||
| OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20240722021721 | ||
| OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|µmol/L|<1000|N|||F|||20240722021721 | ||
| OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20240722021721 | ||
| OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20240722021721 | ||
| OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|µmol/L|<230|N|||F|||20240722021721 | ||
| OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20240722021721 | ||
| OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|µmol/L|<175|N|||F|||20240722021721 | ||
| OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20240722021721 | ||
| OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|µmol/L|<680|N|||F|||20240722021721 | ||
| OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|µmol/L|<6.1|N|||F|||20240722021721 | ||
| OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|µmol/L|6.3-100|N|||F|||20240722021721 | ||
| OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|µmol/L|5-49|N|||F|||20240722021721 | ||
| OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20240722021721 | ||
| OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|µmol/L|<800|N|||F|||20240722021721 | ||
| OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20240722021721 | ||
| OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|µmol/L|<63|N|||F|||20240722021721 | ||
| OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20240722021721 | ||
| OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|µmol/L|<1500|N|||F|||20240722021721 | ||
| OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20240722021721 | ||
| OBR|6|7271235330^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202407171229|||||||||^HUBBARD^EUSTRATIA||||||20240722021721|||F | ||
| OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240722021721 | ||
| OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20240722021721 | ||
| OBR|7|7271235330^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202407171229|||||||||^HUBBARD^EUSTRATIA||||||20240722021721|||F | ||
| OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|µmol/L|6.4-125|N|||F|||20240722021721 | ||
| OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20240722021721 | ||
| OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|µmol/L|10-80|N|||F|||20240722021721 | ||
| OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20240722021721 | ||
| OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|µmol/L|<0.95|N|||F|||20240722021721 | ||
| OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|µmol/L|<0.45|N|||F|||20240722021721 | ||
| OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20240722021721 | ||
| OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|µmol/L|<0.65|N|||F|||20240722021721 | ||
| OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|µmol/L|<0.65|N|||F|||20240722021721 | ||
| OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|µmol/L|<0.45|N|||F|||20240722021721 | ||
| OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|µmol/L|<2|N|||F|||20240722021721 | ||
| OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|µmol/L||N|||F|||20240722021721 | ||
| OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|µmol/L|<1.2|N|||F|||20240722021721 | ||
| OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|µmol/L|<0.9|N|||F|||20240722021721 | ||
| OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20240722021721 | ||
| OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|µmol/L||N|||F|||20240722021721 | ||
| OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|µmol/L|<0.2|N|||F|||20240722021721 | ||
| OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|µmol/L|<12|N|||F|||20240722021721 | ||
| OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|µmol/L|<1.4|N|||F|||20240722021721 | ||
| OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20240722021721 | ||
| OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20240722021721 | ||
| OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|µmol/L|<3.5|N|||F|||20240722021721 | ||
| OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|µmol/L|<7|N|||F|||20240722021721 | ||
| OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|µmol/L||N|||F|||20240722021721 | ||
| OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20240722021721 | ||
| OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20240722021721 | ||
| OBR|8|7271235330^FormNumber||57085-3^Organic acid newborn screen panel|||202407171229|||||||||^HUBBARD^EUSTRATIA||||||20240722021721|||F | ||
| OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|µmol/L|<7.9|N|||F|||20240722021721 | ||
| OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20240722021721 | ||
| OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|µmol/L|<0.48|N|||F|||20240722021721 | ||
| OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|µmol/L|<1.7|N|||F|||20240722021721 | ||
| OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|µmol/L|<0.95|N|||F|||20240722021721 | ||
| OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20240722021721 | ||
| OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|µmol/L|<0.5|N|||F|||20240722021721 | ||
| OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|µmol/L|<1.15|N|||F|||20240722021721 | ||
| OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|µmol/L|<0.38|N|||F|||20240722021721 | ||
| OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20240722021721 | ||
| OBR|9|7271235330^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202407171229|||||||||^HUBBARD^EUSTRATIA||||||20240722021721|||F | ||
| OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20240722021721 | ||
| OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240722021721 | ||
| OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20240722021721 | ||
| OBR|10|7271235330^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202407171229|||||||||^HUBBARD^EUSTRATIA||||||20240722021721|||F | ||
| OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<85|N|||F|||20240722021721 | ||
| OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240722021721 | ||
| OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240722021721 | ||
| OBR|11|7271235330^FormNumber||54090-6^Thyroid newborn screening panel|||202407171229|||||||||^HUBBARD^EUSTRATIA||||||20240722021721|||F | ||
| OBX|1|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20240722021721 | ||
| OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240722021721 | ||
| OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240722021721 | ||
| OBR|12|7271235330^FormNumber||54079-9^Galactosemia newborn screening panel|||202407171229|||||||||^HUBBARD^EUSTRATIA||||||20240722021721|||F | ||
| OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|55.00|enzyme units|>50|N|||F|||20240722021721 | ||
| OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240722021721 | ||
| OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240722021721 | ||
| OBR|13|7271235330^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202407171229|||||||||^HUBBARD^EUSTRATIA||||||20240722021721|||F | ||
| OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20240722021721 | ||
| OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20240722021721 | ||
| OBR|14|7271235330^FormNumber||57087-9^Biotinidase newborn screening panel|||202407171229|||||||||^HUBBARD^EUSTRATIA||||||20240722021721|||F | ||
| OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20240722021721 | ||
| OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240722021721 | ||
| OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240722021721 | ||
| OBR|15|7271235330^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202407171229|||||||||^HUBBARD^EUSTRATIA||||||20240722021721|||F | ||
| OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|2|copies/µL|>18|L|||F|||20240722021721 | ||
| OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20240722021721 | ||
| OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Positive|||A|||F|||20240722021721 | ||
| OBR|16|7271235330^FormNumber||63414-7^Pompe Disease newborn screening panel|||202407171229|||||||||^HUBBARD^EUSTRATIA||||||20240722021721|||F | ||
| OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|µmol/L/h|>=2.079|N|||F|||20240722021721 | ||
| OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240722021721 | ||
| OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20240722021721 | ||
| OBR|17|7271235330^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202407171229|||||||||^HUBBARD^EUSTRATIA||||||20240722021721|||F | ||
| OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|µmol/L/h|>=1.2204|N|||F|||20240722021721 | ||
| OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240722021721 | ||
| OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240722021721 | ||
| OBR|18|7271235330^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202407171229|||||||||^HUBBARD^EUSTRATIA||||||20240722021721|||F | ||
| OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20240722021721 | ||
| OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240722021721 | ||
| OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20240722021721 | ||
| OBR|19|7271235330^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202407171229|||||||||^HUBBARD^EUSTRATIA||||||20240722021721|||F | ||
| OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20240722021721 | ||
| OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20240722021721 | ||
| OBR|20|7271235330^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202407171229|||||||||^HUBBARD^EUSTRATIA||||||20240722021721|||F | ||
| OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|µmol/L|<0.47|N|||F|||20240722021721 |
Oops, something went wrong.